Arrowhead to Report Fiscal 2015 Third Quarter Financial Results
July 28 2015 - 4:30PM
Business Wire
- Conference Call Scheduled for Tuesday, August
4, 2015
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that it will report its financial results for the
fiscal 2015 third quarter ended June 30, 2015, on Tuesday, August
4, 2015, at 4:30 p.m. EDT. Investors may access a live audio
webcast on the Company's website at
http://ir.arrowheadresearch.com/events.cfm. For analysts that wish
to participate in the conference call, please dial 315-625-6887 and
enter Conference ID 97375077.
A replay of the webcast will be available on the company’s
website approximately two hours after the conclusion of the call
and will remain available for 90 days. An audio replay will also be
available approximately two hours after the conclusion of the call
and will be available for 3 days. To access the audio replay, dial
404-537-3406 and enter Conference ID 97375077.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 for chronic hepatitis B virus and ARC-AAT for
liver disease associated with Alpha-1 antitrypsin deficiency.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Arrowhead Research Corporation's most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss
some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no
obligation to update or revise forward-looking statements to
reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Research Corporation.
Source: Arrowhead Research Corporation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150728006804/en/
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupTodd James646-378-2926ir@arrowres.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Sep 2023 to Sep 2024